Tag: hematology

Tyrosine Kinase Inhibitor Discontinuation Can Improve CML Outcomes

NEW YORK (Reuters Health) – In patients with chronic myeloid leukemia (CML), discontinuing tyrosine kinase inhibitor (TKI) therapy is safe and associated with better patient-reported...

Patients and Physicians’ Priorities Around AML Decisions in Older Patients Misaligned

Patient and physician priorities around therapy decision-making do not always align, shows an international qualitative study investigating the influences underpinning disease-management decisions in patients with...

Renal Function Decline With TKI Use in Chronic Myeloid Leukaemia

Renal function declines over time with tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukaemia (CML), although it is unclear if the relationship is causal,...

Post-Dental Extraction Bleeding Decreases With Mouth Splints

Dental extractions can cause significant risk of bleeding in hemophilia patients being treated with factor replacements. However, mouth splints significantly decreased the risk of postextraction...

A Guide to the New Agents Reshaping Ovarian Cancer Treatment

The treatment of ovarian cancer has evolved considerably in the last few years, with the approval of several PARP inhibitors, antiangiogenic agents, and other therapies...

Fewer Seizures, Increased Thrombocytopenia Risk

Two recently completed analyses of highly purified cannabidiol (CBD) used to reduce seizures in Lennox Gastaut syndrome (LGS) have shown the formulation as an add-on...

‘Impressive’ Outcomes Sans Chemo in Poor-Prognosis ALL

The days of using chemotherapy to treat Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) may be numbered. In a phase 2 trial, up-front chemo-free induction/consolidation...

EMA OKs First CAR T-Cell Therapy for Mantle Cell Lymphoma

The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to brexucabtagene autoleucel (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for...

Once-Weekly Investigational MK-8507 Potent Even at Low Doses

A single dose of MK-8507, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), reduced HIV-1 viral loads for at least 1 week with efficacy comparable to...

7 Things to Know About New Lymphoma Drug Tafasitamab

The US Food and Drug Administration (FDA) recently approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse...

Cell Therapy for Anthracycline Cardiomyopathy Safe, Feasible

In yet another trial of cell therapy for heart failure, this time in cancer survivors with anthracycline-induced cardiomyopathy (AIC), administration of allogeneic bone marrow-derived mesenchymal...

Identifying Patients With Indolent Disease

Mantle cell lymphoma (MCL) can run the gamut from an indolent to aggressive disease, and identifying biomarkers is key in determining which patients should follow...

Hair Dye and Cancer Study ‘Offers Some Reassurance’

The largest study of its kind has found no positive association between personal use of permanent hair dye and the risk for most cancers and...

FDA Approves First Maintenance Therapy for AML

The US Food and Drug Administration (FDA) has approved an oral form of azacitidine (Onureg) for use as maintenance therapy for patients with acute myeloid...

REALITY Trial Supports Restrictive Transfusion in Anemic MI

A restrictive blood transfusion strategy in myocardial infarction patients with anemia proved safe, significantly less costly, and at least as effective as the standard liberal...

Performance Status, Molecular Testing Key to Cancer Prognosis

Performance status and molecular testing results are key tools in prognosticating for patients with newly diagnosed metastatic solid tumors, according to Sam Brondfield, MD, MA,...

Novel Oral Drug Improves Sunlight Tolerance

Dersimelagon, a novel once-daily oral selective melanocortin-1 receptor agonist, significantly boosted sunlight tolerance in patients with erythropoietic protoporphyria in a multicenter, phase 2, randomized trial,...

FDA OKs Ofatumumab (Kesimpta) for Relapsing Forms of MS

The US Food and Drug Administration (FDA) has approved ofatumumab injection (Kesimpta, Novartis) for the treatment of adults with relapsing forms of multiple sclerosis, including...

Ofatumumab Phase 3 Multiple Sclerosis Trials Published

Two phase 3 clinical trials showing impressive results with the new subcutaneously-delivered, B-cell depleting multiple sclerosis anti-CD20 mononclonal antibody ofatumumab (Arzerra) have now been published...

All NSAIDs Raise Post-MI Risk but Some Are Safer: Next Chapter

Patients on antithrombotics after an acute myocardial infarction (MI) will face a greater risk for bleeding and secondary cardiovascular (CV) events if they start taking...

FDA Approves New Drug for Diffuse Large B-Cell Lymphoma

A novel drug, tafasitamab-cxix (Monjuvi, MorphoSys US Inc), has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients...

Higher Death Rate in Cancer Patients With Nosocomial COVID-19

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Hospitalized cancer patients have a high risk of nosocomial COVID-19 that...

Blood Type Not Linked to COVID-19 Severity

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Blood type is not a predictor of COVID-19 severity (death or...

Don’t Overlook Treating Older Patients With APL, Expert Says

The estimated one third of patients with acute promyelocytic leukemia (APL) who are older than 60 years of age now enjoy a notably better prognosis...

Stem Cell Strategies Get Compassionate Use in COVID-19

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. The COVID-19 pandemic has inspired quests for treatments new and retooled....